Lyell Immunopharma (LYEL) Other Operating Expenses (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Other Operating Expenses data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 1493.28% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (up 67.75% YoY), and the FY2025 full-year result was $2.1 million, down 35.18% from the prior year.
• Other Operating Expenses improved to $1.9 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $1.9 million in Q1 2026 to a low of -$1.1 million in Q2 2025.
• A 5-year average of $876117.6 and a median of $1.1 million in 2024 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses plunged 208.81% in 2025 and soared 1493.28% in 2026, its largest moves.
• Tracing LYEL's Other Operating Expenses over 5 years: stood at $1.2 million in 2022, then slumped by 47.02% to $641000.0 in 2023, then slipped by 19.97% to $513000.0 in 2024, then surged by 191.81% to $1.5 million in 2025, then rose by 26.65% to $1.9 million in 2026.
• Business Quant data shows LYEL's Other Operating Expenses at $1.9 million in Q1 2026, $1.5 million in Q4 2025, and $1.6 million in Q3 2025.